This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Memantine improves goal attainment and reduces caregiver burden in Parkinson’s disease with dementia


Leroi, Iracema, Atkinson, Richard, Overshott, Ross


International Journal of Geriatric Psychiatry, Volume: 29, No.: 9, Pages.: 899-905

Year of Publication



Objective: Memantine, an uncompetitive antagonist of N‐methyl‐D‐aspartate receptors, may have a role in managing symptoms associated with dementia in Parkinson’s disease (PDD), although its role in improving patient‐reported outcomes (PROs) has not been extensively investigated. PROs may be more sensitive than standard psychometric measures for detecting change in complex conditions such as PDD. The aim of this study was to examine the effect of memantine on PROs: individually determined goals and health‐related quality of life. We also examined memantine’s effect on caregiver burden. Methods: This 22‐week double‐blind randomised controlled trial evaluated participants with PDD on 20 mg of memantine or placebo. Outcome measures were Goal Attainment Scaling (GAS), the Parkinson’s Disease Questionnaire‐8 and the Zarit Burden Inventory. Results: A significantly greater proportion of participants on memantine (64%) had better than expected GAS outcomes compared with those on placebo (7%) (p = 0.007). Furthermore, the improvement in mean GAS score, as well as mean caregiver burden score, from baseline to drug discontinuation was significantly greater in those on memantine compared with those on placebo (p = 0.03 and 0.04, respectively). Significant differences in quality of life were not seen. Conclusions: In this study, memantine improved individually set goals and caregiver burden in PDD. This suggests that clinimetric measures such as GAS may be more sensitive than conventional psychometric measures in detecting improvements in people with PDD. (PsycINFO Database Record (c) 2014 APA, all rights reserved). (journal abstract)

Bibtex Citation

@article{Leroi_2014, doi = {10.1002/gps.4077}, url = {}, year = 2014, month = {feb}, publisher = {Wiley-Blackwell}, volume = {29}, number = {9}, pages = {899--905}, author = {Iracema Leroi and Richard Atkinson and Ross Overshott}, title = {Memantine improves goal attainment and reduces caregiver burden in Parkinson{textquotesingle}s disease with dementia}, journal = {Int J Geriatr Psychiatry} }


caregiver burden, dementia, drug therapy, goal attainment, memantine, nmethyldaspartate, parkinsons disease, parkinsons disease dementia, quality of life, symptoms, treatment effectiveness evaluation

Countries of Study


Types of Dementia

Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes

Carer Burden (instruments measuring burden), Depression and Anxiety, Quality of Life of Carer

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime